Psyence Biomedical (PBM) Liabilities and Shareholders Equity (2023 - 2025)

Psyence Biomedical's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $12.8 million for Q3 2025.

• In Q3 2025, Liabilities and Shareholders Equity rose 468.46% year-over-year to $12.8 million; the TTM figure through Sep 2025 stood at $23.5 million (changed N/A YoY), while the FY2025 annual figure was $7.3 million, up 546.23% from the prior year.
• Liabilities and Shareholders Equity was $12.8 million for Q3 2025 at Psyence Biomedical, up from $7.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.8 million in Q3 2025 to a low of $1.1 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $5.0 million across 3 years, with a median of $2.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity declined 28.81% in 2024, then jumped 546.23% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $1.6 million in 2023, then soared by 41.71% to $2.3 million in 2024, then soared by 468.46% to $12.8 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $12.8 million (Q3 2025), $7.3 million (Q1 2025), and $2.3 million (Q3 2024), per Business Quant data.